紫杉醇联合顺铂治疗蒽环类耐药晚期乳腺癌的临床观察 DOC 格式论文,方便您的复制修改删减紫杉醇联合顺铂治疗蒽环类耐药晚期乳腺癌的临床观察(作者:___________ 单位: ___________ 邮编: ___________ ) 【摘要】目的: 评价紫杉醇联合顺铂(TP) 方案治疗蒽环类耐药晚期乳腺癌的疗效。方法: 2003 年1 月~ 2007 年1 月采用 TP 方案( 紫杉醇+ 顺铂) 治疗了 32 例蒽环类耐药的晚期乳腺癌, 观察治疗效果及不良反应发生率。结果:完全缓解(CR)2 例(%), 部分缓解(PR)15 例(%), 稳定(SD)12 例(%), 进展(PD)3 例(%), 总有效率为 %; 全组中位疾病进展时间(TTP) 个月,中位生存时间(MST) 个月, 1 年生存率 %; 主要不良反应为骨髓抑制、胃肠道反应和脱发。结论: 紫杉醇联合顺铂方案治疗蒽环类耐药晚期乳腺癌有较好的疗效且不良反应可以耐受。【关键词】紫杉醇; 顺铂; 晚期乳腺癌; 蒽环类[ABSTRACT] Objective: To evaluate the efficacy and toxicity of p aclitaxelcisplatin therapy in treating anthracycineresistant advanced breast cancer. Methods : From to ,a total of 32 patients with anthracycineresistant advanced breast DOC 格式论文,方便您的复制修改删减 cancer were treated with paclitaxelcisplatin : Two cases(%)plete response(CR) , 15 cases(%)had partial response(PR) , while 12 cases(%) had stable disease(SD)and 3 cases(%) had progressive disease(PD);The overall response rate was %, with a median progression time as median survival time was 1year overall survival rate was %. The major side effects were myelosuppression , gastrointestinal toxicity and alopecia. Conclusion : bined with cisplatin is an effective trea temnt for patients with anthracycineresistant advanced breast side effects are tolerable. [KEY
